A Phase 1 Open-label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor alpha (FolRa) Antibody Drug Conjugate (ADC), in Combination with Bevacizumab in Patients with Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers)

Protocol No
SUTRO-STRO-002-GM2
Principal Investigator
Denise Uyar
Phase
I
Summary
n this study, we want to find out more about the side effects (problems and symptoms) of an experimental drug for cancer, STRO-002, in combination with an approved drug, bevacizumab, and what doses of STRO-002 and bevacizumab together are safe for people to take.
Description
STRO-002 With Bevacizumab in Epithelial Ovarian Cancer
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Sub Category